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ARTICLE
The profile of patients followed at the 
Neuroimmunology Clinic at UNIFESP: 20 years 
analysis
O perfil de pacientes atendidos no setor de Neuroimunologia da UNIFESP: análise de 20 anos
Denis Bernardi Bichuetti, Alessandra Billi Falcão, Fernanda de Castro Boulos, Marilia Mamprim de Morais, 
Claudia Beatriz de Campos Lotti, Manuela de Oliveira Fragomeni, Maria Fernanda Campos, Nilton Amorim 
de Souza, Enedina Maria Lobato Oliveira
Multiple sclerosis (MS) and neuromyelitis optica 
(NMO) are the most important and common inflammatory 
autoimmune diseases that affect the central nervous system 
(CNS) and can lead to sustained neurologic disability and 
financial burden for the society1,2. Both diseases can cause 
visual impairment, pyramidal deficits, sensation loss, neu-
ropathic pain, coordination problems, gait impairment and 
cognitive problems (more MS than NMO). While MS has a 
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ABSTRACT
Objective: To describe the clinical activities at the Neuroimmunology Clinic of the Universidade Federal de São Paulo (UNIFESP) from 1994 
to 2013. Method: The final diagnosis of all patients that attended the center was reviewed and established upon specific guidelines for 
each disease. The number of total appointments and extra clinical activities (reports and prescriptions) were also analyzed, as are part of 
routine activities. Results: 1,599 patients attended the Clinic from 1994 to 2013: 816 with multiple sclerosis (MS), 172 with clinical isolated 
syndromes, 178 with neuromyelitis optica (NMO), 216 with other demyelinating disease, 20 with metabolic disorder, 42 with a vascular 
disease and 155 with other or undetermined diagnosis. A mean 219 outpatient visits and 65 extra clinical activities were performed monthly. 
Conclusion: We identified that 15% of patients seen have NMO. As patients with NMO have a more severe disease than MS, this data may 
be important for planning local health care policies.
Keywords: multiple sclerosis, neuromyelitis optica, epidemiology, Sao Paulo.
RESUMO
Objetivo: Descrever a casuística de pacientes atendidos no setor de Neuroimunologia da Universidade Federal de São Paulo (UNIFESP) de 
1994 a 2013. Método: Analisamos o diagnóstico final de todos os pacientes atendidos de 1999 a 2013, sendo o diagnóstico revisado na última 
consulta e estabelecido de acordo com os critérios específicos para cada doença. O volume de atendimentos clínicos e não clínicos (relatórios 
e receitas) foram contabilizados para avaliar a carga de trabalho da equipe. Resultados: 1.599 pacientes foram avaliados: 816 com esclerose 
múltipla (EM), 172 com síndromes clínicas isoladas, 178 com neuromielite óptica (NMO), 216 com outras doenças desmielinizantes, 20 com 
doenças metabólicas, 42 com doenças vasculares e 155 com outros diagnósticos ou diagnósticos indefinidos. Identificamos uma média de 
219 consultas e 65 solicitações de relatórios por mês. Conclusão: Identificamos que 15% dos pacientes atendidos tem NMO. Por ser uma 
doença mais incapacitante que a EM estes dados podem ser importantes para o planejamento de políticas de saúde locais.
Palavras-chave: esclerose múltipla, neuromielite óptica, epidemiologia, São Paulo.
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stepwise or continuously progressive initial presentations, 
known as relapsing remitting multiple sclerosis (RRMS) or 
primary progressive multiple sclerosis (PPMS), NMO does 
not have a progressive clinical course and neurologic im-
pairments are solely relapse dependent3,4,5. The diagnosis 
of both diseases are made with a combination of clinical 
signs and symptoms, specific magnetic resonance imag-
ing criteria, cerebrospinal fluid analysis, electrophysiologi-
cal studies and the exclusion of other causes for the spe-
cific symptoms6,7. For NMO there is also a specific serum 
antibody that targets the aquaporin-4 water channel at the 
blood-brain-barrier available for disease confirmation7, also 
called NMO-IgG.
The prevalence of MS rises in higher latitudes, rang-
ing from 20/100,000 to nearly 90/100,000 in the northern 
hemisphere countries, possibility related to sun exposure, 
genetics of specific populations in these areas and others 
yet unknown environmental factors8,9. The prevalence of 
MS in the city of Sao Paulo and Belo Horizonte, two ma-
jor Brazilian cities, are estimated around 15/100,00010 and 
18/100,000 inhabitants11 and, although they might not re-
flect the real national data, they are the most accurate in-
formation on the theme to date.
The prevalence of NMO, on the other hand, ranges from 
0.5 to 4.4/100,000 inhabitants in North America and Europe, 
but this data is unknown in Brazil. NMO affects more fre-
quently African-Descendants and Asian populations12 than 
Caucasians, and since Brazil is a country of mixed ethnic 
population its prevalence might be higher in Brazil than in 
other countries. This is supported by studies that disclosed 
specific genetics risk factor for NMO in Brazil13,14,15.
Additionally, in North America and European countries 
MS is known to be the main cause of disability and retire-
ment in people under 50 years old16 and, although this in-
formation is not clearly available for Brazil, national stud-
ies disclose that patients with NMO have a more severe 
disease than patients with RRMS, including higher risk of 
becoming wheelchair bound and dying of a demyelinat-
ing disease12, which reinforces the need of information on 
these disease, as it may have social and economic impact. 
It is important to state that both diseases are treatable and 
that neurologic disability can be avoided or postponed 
with specific medications, some of them available from the 
Sistema Único de Saúde (SUS), the Brazilian Public Health 
Care System17.
The aim of this study is to present the 20-year descrip-
tive analysis of patients attending the Neuroimmunology 
Clinic of the Universidade Federal de São Paulo (UNIFESP), 
not only regarding specific clinical diagnosis and the rate of 
MS and NMO, but also expose clinical background activities 
such as performing medical reports and filling medication 
prescriptions renovations, offering information that could be 
used by health care authorities in creating a plan of care for 
these patients.
METhOd
The Neuroimmunology Clinic of the UNIFESP is a public 
tertiary care center focused on caring for patients with mul-
tiple sclerosis and other demyelinating diseases, established 
in 1994, and located at Hospital São Paulo, the main general 
hospital at the UNIFESP complex. Since then, the center keeps 
a database containing all clinical, laboratory, radiological and 
therapeutic information of all the patients attending the clinic. 
All patients attending the clinic are invited to participate in a 
prospective registry approved by the university’s institutional 
review board and sign a written informed consent for clini-
cal and radiological data storage and analysis. This study is a 
cross-sectional evaluation of this database, encompassing all 
patients evaluated from 1994 to December 31st 2013.
We retrieved the final diagnosis of all patients that had an 
appointment at our center; the diagnosis of each subject was 
always reviewed at the last follow up appointment and was 
made according to specific guidelines at the time they were 
last seen. The patients are allocated in the following catego-
ries, followed by some examples:
1) Multiple sclerosis (MS): relapsing-remitting MS, prima-
ry-progressive MS and secondary-progressive MS;
2) Clinical isolated syndromes (CIS): optic neuritis, par-
tial transverse myelitis and brainstem syndromes either with 
brain lesions suggestive of MS (meeting treatment criteria18) 
or not, but not meeting current criteria for NMO7,19 or other 
diseases;
3) Neuromyelitis optica spectrum disorders (NMO-SD): 
classical NMO7,19, longitudinally extensive spinal cord lesions 
(recurrent or single episode with positive NMO-IgG), relaps-
ing optic neuritis (recurrent or single episode with positive 
NMO-IgG) or brainstem or cerebral inflammatory syndromes 
with positive NMO-IgG2,20;
4) Other demyelinating disease: adrenoleukodistrophy, 
Krabbe disease and metachromatic leukodistrophy, among 
others;
5) Metabolic disorder: vitamin B12 deficiency, muscle 
metabolism disorders;
6) Vascular disease: multiple cerebral infarcts (“etat lacu-
naire”), spinal cord infarct and others related to cerebrovas-
cular disease;
7) Other diagnosis: mitochondrial neurogastrointestinal 
encephalopathy, HTLV associated tropical spastic parapare-
sis, psychiatric disease, mitochondrial diseases, other degen-
erative disorders (multiple system atrophy and other atypical 
parkinsonian syndromes);
8) Undetermined: patients that we could not determine 
the diagnosis either due to unavailability of specific tests or 
inconclusive investigation.
When the diagnosis was MS and NMO, we also evaluated 
the number of patients that presented the first symptom be-
fore completing 18 or after 50 years of age, as these are the cur-
rent literature definitions for pediatric and late onset diseases, 
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respectively21,22. All patients were offered regular preventive ther-
apies recommended and available for their diagnosis (MS or 
NMO) at the time they were seen, which included, but were not 
restricted to, interferon beta, glatiramer acetate, natalizumab, 
fingolimod, corticosteroids, cyclophosphamide, methotrexate, 
azathioprine, plasma exchange and IV immunoglobulin20,23.
We also reviewed the number of total appointments as 
well as the number of reports requested (medical reports for 
job applications, early retirement, benefices for the handi-
capped, medication usage for international travelers and oth-
ers) and medications prescriptions renewal demanded by the 
patients, as these are part of the “off clinic” regular patient 
care activities. It is important to say that the Brazilian public 
healthcare system, Sistema Único de Saúde (SUS), requires 
that all patients present a new medication prescription every 
three months, in order to maintain regular supply, an impor-
tant part of the “off clinic” described above. Since a complete 
computerized system for all outpatient activity was only im-
plemented on the second semester of 2013, the clinical activity 
information was evaluated from August 1st 2013 to December 
31st 2013 (5 months). The intention of this report is to describe 
the outpatient clinic population, therefore we did not include 
appointments made at the emergency department nor clini-
cal, prognostic and treatment response information, available 
in previous studies from our group5,12,24,25,26,27.
RESUlTS
We identified 1,599 patients that attended the 
Neuroimmunology Clinic at least once from 1994 to 2013, 
2/3 of them with MS and NMO (Figure). We then evaluated 
separately only the patients with recurrent primary autoim-
mune demyelinating disease of the central nervous system, 
MS and CIS in a single group and NMO as a distinct group, re-
vealing a total of 1,166 patients: 988 with MS/CIS (84.7%) and 
178 (15.3%) with NMO and NMO-SD (Figure). From the total-
ity of patients with MS, 7% presented as pediatric onset and 
4% as late onset, and 4% of the patients with NMO presented 
as pediatric onset whereas 7% as late onset.
The activities performed by the staff from August 1st 2013 
to December 31st 2013 (5 months) summed 55 clinical ap-
pointments and 16 “off clinic” activities per week (Table).
Table. Outpatient visits and activities performed by the staff.
  Mean by month* Mean by week Yearly**
Outpatient visits* 219 55 2,413
Reports and medical prescriptions*** 65 16 712
*Data from August 1st 2013, to December 31st 2013 (5 months). **Yearly estimative considering 11 working months. Values obtained from multiplying the “mean 
by month” for 11 working months, as the University seizes outpatient activities on Christmas and New Year’s and national holidays. ***Only registered requests 
performed outside clinical appointments, as some reports and medication prescriptions are also filled during outpatient visits.
Undetermined
Other diagnosis
Vascular disease
Metabolic disorder
ODD
NMO-SD
CIS
MS
0 200 400 600 800 1,000
816 (51.1%)
172 (10.8%)
178 (11.1%)
216 (13,5%)
20 (1.3%)
42 (2.6%)
108 (6.8%)
47 (2.9%)
All patients (n = 1,599)
Number of patients
MS+CIS and NMO only (n = 116)
MS NMO-SD
178
(15.3%)
988
(84.7%)
Figure. Total number of patients that attended the Neuroimmunology Clinic by final diagnosis. Left: Sum by all diagnosis; 
Right: Recurrent primary autoimmune demyelinating disease of the central nervous system, i.e., MS and CIS in a single group and 
NMO-SD. MS: Multiple sclerosis (relapsing remitting and primary progressive onset of MS forms); CIS: Clinical isolated syndrome (optic 
neuritis, partial transverse myelitis and brainstem syndromes either with brain lesions suggestive of MS (meeting treatment criteria18) 
or not, but not meeting current criteria for NMO7,19 or other diseases); NMO-SD: Neuromyelitis optica spectrum disorders; ODD: Other 
demyelinating disease. Data includes patients that performed at least one appointment at the Clinic between 1994 and 2013.
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dISCUSSION
This study discloses that 15.3% of patients with primary 
autoimmune demyelinating diseases of the central nervous 
system followed at a specialized tertiary care center in the 
city of Sao Paulo have NMO-SD, a number nearly 10 times 
higher that reported for North America or Europe2. Given 
that patients with NMO have a more severe disease than MS, 
this may have implications on health care and society costs, 
and should be the focus of local policies. The numbers of pe-
diatric and late onset cases reported are similar to other na-
tional and international centers24,25.
One third of the patients evaluated at the clinic did not 
have MS or NMO, which is not surprising as patients are re-
ferred to us for diagnostic confirmation from primary care 
physicians or general neurologists28. These patients are either 
referred back to their primary doctors or to the specific clin-
ic within our neurology department for follow up and treat-
ment and this rate should not be used to evaluate the sys-
tem’s efficiency.
As expected in any routine medical practice, the work 
performed by the staff is not restricted to the time allocat-
ed in direct patient care (Table), as “off clinic” duties include 
regular care paperwork (prescriptions and reports), phone 
and e-mail answering, which are very difficult to keep track, 
and administrative meetings. Many medications available at 
the SUS, especially the ones considered of high costs, such 
as the ones used for the treatment of MS and NMO, needs 
prescription renovation every 3 months17, which increases 
the need for follow-up appointments in an already busy and 
overloaded clinic, and the creation of an extra agenda for re-
ports and prescription refilling, as they are constantly need-
ed in order to keep patients under regular treatment. These 
activities should be taken into account when planning the 
staff required and their working duties for a specialized ser-
vice as this one.
The plan of care in our clinic is one appointment every 3 
months in the first year after diagnosis and every 6 months 
on the following years, excepts when new symptom demand 
earlier and urgent evaluation. Since many patients have a con-
comitant follow-up with an external neurologist, either private 
or within their health care insurance, and come to the clinic 
on a yearly or as needed basis, such as medication switch or 
treatment reassurance, the number of outpatients visit do not 
exactly reflect the total work demanded by patients with NMO 
or MS. Thus, considering the number of outpatient visits re-
quired if these patients were 100% dependent on the UNIFESP 
clinic, the number of appointments offered today would not be 
sufficient. Furthermore, emergency service visits, the use of an 
infusion facility for medication administration and inpatient 
care were also not reported in this study, which are all part of 
caring for someone with MS or NMO, were not evaluated in 
this work, as well as teaching and research activities, an impor-
tant part of a university hospital staff.
Demyelinating diseases demand a complex care which 
should be focused on early diagnosis and treatment with the 
intention to prevent neurologic disability. Considering that 
patients with NMO present a more debilitating disease with-
in an earlier timeframe than patients with MS, the current 
work emphasizes the need of an early and correct diagnosis, 
since one should expect NMO prevalence be higher among 
Brazilians. The creation of a collaborative network to collect 
information on patient care should be the next step in order 
to update the prevalence of MS and NMO in the city of Sao 
Paulo and provide data to healthcare providers that could be 
used in future planning for public policies and patient care.
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